Valneva Q1 Earnings Call Highlights

Impact · against what's priced in

Valneva's outlook is significantly dampened by lowered 2026 revenue guidance and widening losses driven by operational inefficiencies. Conversely, Pfizer's decision to proceed with regulatory filings for the Lyme vaccine despite a statistical miss provides a positive, though risk-laden, catalyst.

VALN−0.70: No priced-in read yet
In context: The company lowered 2026 revenue guidance to 145-160 million euros due to adverse travel trends and reported a widened net loss of 32.1 million euros caused by contracting gross margins and manufacturing failures.
Read from the article alone

biotech▲9%
earnings▲4%
guidance
PFE
VALN
cash burn
clinical trials
layoffs

Valneva Q1 Earnings Call Highlights

What matters in this story

BHP, Rio Tinto and Fortescue hit multi-month lows as miners come under pressure

Valneva Q1 Earnings Call Highlights

What matters in this story

BHP, Rio Tinto and Fortescue hit multi-month lows as miners come under pressure

How each ticker is affected

Connected tickers

Track these names every morning.

BancFirst (BANF) Beats Q3 Earnings and Revenue Estimates

Pathward Financial (CASH) Surpasses Q4 Earnings and Revenue Estimates

Cathay General (CATY) Q3 Earnings Lag Estimates

Armour Residential REIT (ARR) Q3 Earnings Lag Estimates

Valneva Q1 Earnings Call Highlights

What matters in this story

Next reads from the same story arc

BHP, Rio Tinto and Fortescue hit multi-month lows as miners come under pressure

Valneva Q1 Earnings Call Highlights

What matters in this story

Next reads from the same story arc

BHP, Rio Tinto and Fortescue hit multi-month lows as miners come under pressure

How each ticker is affected

Connected tickers

Track these names every morning.

BancFirst (BANF) Beats Q3 Earnings and Revenue Estimates

Pathward Financial (CASH) Surpasses Q4 Earnings and Revenue Estimates

Cathay General (CATY) Q3 Earnings Lag Estimates

Armour Residential REIT (ARR) Q3 Earnings Lag Estimates